Soligenix Inc. (NASDAQ:SNGX – Free Report) – Equities researchers at Zacks Research issued their Q1 2026 earnings estimates for shares of Soligenix in a research note issued to investors on Monday, April 6th. Zacks Research analyst D. Bautz anticipates that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Research also issued estimates for Soligenix’s Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.25) EPS and FY2028 earnings at ($0.78) EPS.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.00.
Soligenix Stock Performance
NASDAQ:SNGX opened at $1.14 on Tuesday. Soligenix has a fifty-two week low of $1.00 and a fifty-two week high of $6.23. The stock has a market capitalization of $11.75 million, a P/E ratio of -0.32 and a beta of 1.93. The company’s 50-day simple moving average is $1.17 and its 200-day simple moving average is $1.36.
Institutional Trading of Soligenix
Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in Soligenix during the 4th quarter valued at approximately $37,000. StoneX Group Inc. acquired a new stake in Soligenix during the 4th quarter valued at approximately $50,000. Jane Street Group LLC acquired a new stake in Soligenix during the 4th quarter valued at approximately $51,000. Banco BTG Pactual S.A. acquired a new stake in Soligenix during the 3rd quarter valued at approximately $54,000. Finally, Virtu Financial LLC acquired a new stake in Soligenix during the 3rd quarter valued at approximately $59,000. 3.60% of the stock is currently owned by institutional investors and hedge funds.
About Soligenix
Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.
The company’s pipeline is organized into two core divisions.
See Also
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
